(Reuters) – Drug development software maker Pharsight Corp (PHST.O) agreed to be bought by privately held Tripos International for about for about $57 million in cash, the companies said in a joint statement.
Pharsight shareholders will receive $5.50 a share, which represents a premium of nearly 38 percent to the company’s Monday closing price of $3.99.
The deal is expected to close in the fourth quarter of 2008.
Covington Associates acted as financial advisor to Pharsight. Tripos is owned by private-equity firm Vector Capital.
Shares of Mountain View, California-based Pharsight were halted when the market opened.
(Reporting by Varsha Tickoo in Bangalore; Editing by Himani Sarkar)